Medullary thyroid cancer: RET testing of an archival material

被引:7
|
作者
Godballe, Christian [1 ]
Jorgensen, Gita [1 ]
Gerdes, Anne-Marie [2 ,3 ]
Krogdahl, Annelise S. [4 ]
Tybjaerg-Hansen, Anne [5 ]
Nielsen, Finn C. [5 ]
机构
[1] Odense Univ Hosp, Dept ENT Head & Neck Surg, DK-5000 Odense, Denmark
[2] Odense Univ Hosp, Dept Clin Genet, DK-5000 Odense, Denmark
[3] Copenhagen Univ Hosp, Dept Clin Genet, Copenhagen, Denmark
[4] Odense Univ Hosp, Dept Clin Pathol, DK-5000 Odense, Denmark
[5] Copenhagen Univ Hosp, Dept Clin Biochem, Copenhagen, Denmark
关键词
Thyroid; Cancer; Medullary; Hereditary; MULTIPLE ENDOCRINE NEOPLASIA; PROTOONCOGENE MUTATIONS; GERMLINE MUTATIONS; PROGNOSTIC-FACTORS; CARCINOMA; 2A; FAMILIES;
D O I
10.1007/s00405-009-1115-4
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Medullary thyroid carcinoma (MTC) might be sporadic (75%) or hereditary (25%). Until the mid nineties the diagnosis of hereditary MTC was based on family history, clinical evaluation, histological detection of C-cell hyperplasia and tumor multifocality. Patients and families with hereditary MTC might be missed? Today mutation analysis of the RET proto-oncogene is routinely performed on DNA. Departments of pathology often store tissue specimens from performed surgical procedures. The purpose of this study was to examine if analysis of DNA extracted from formalin fixed archival tissue might be a possible method to identify not previously known cases of hereditary MTC. In 23 cases, tissue analysis was performed, and in 2 patients (9%) a mutation was identified, but in both cases the most likely explanation was contamination with tumor tissue. The ability to detect RET mutations was confirmed by testing of non-tumor tissue from patients with known hereditary MTC. This study shows that genetic testing of archival MTC material is technically possible and might be a way of identifying patients with previously not recognized hereditary MTC.
引用
收藏
页码:613 / 617
页数:5
相关论文
共 50 条
  • [41] RET Splice Site Variants in Medullary Thyroid Carcinoma
    Chatzopoulos, Kyriakos
    Saeed-Vafa, Daryoush
    Hernandez-Prera, Juan
    Cano, Pedro
    Saller, James
    McIver, Bryan
    Boyle, Theresa
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 387 - 388
  • [42] RET mutation and increased angiogenesis in medullary thyroid carcinomas
    Verrienti, Antonella
    Tallini, Giovanni
    Colato, Chiara
    Boichard, Amelie
    Checquolo, Saula
    Pecce, Valeria
    Sponziello, Marialuisa
    Rosignolo, Francesca
    de Biase, Dario
    Rhoden, Kerry
    Casadei, Gian Piero
    Russo, Diego
    Visani, Michela
    Acquaviva, Giorgia
    Ferdeghini, Marco
    Filetti, Sebastiano
    Durante, Cosimo
    ENDOCRINE-RELATED CANCER, 2016, 23 (08) : 665 - 676
  • [43] Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
    Oczko-Wojciechowska, Malgorzata
    Swierniak, Michal
    Krajewska, Jolanta
    Kowalska, Malgorzata
    Kowal, Monika
    Stokowy, Tomasz
    Wojtas, Bartosz
    Rusinek, Dagmara
    Pawlaczek, Agnieszka
    Czarniecka, Agnieszka
    Szpak-Ulczok, Sylwia
    Gawlik, Tomasz
    Chmielik, Ewa
    Tyszkiewicz, Tomasz
    Nikiel, Barbara
    Lange, Dariusz
    Jarzab, Michal
    Wiench, Malgorzata
    Jarzab, Barbara
    SCIENTIFIC REPORTS, 2017, 7
  • [44] Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities
    Machens, A.
    Lorenz, K.
    Dralle, H.
    JOURNAL OF INTERNAL MEDICINE, 2009, 266 (01) : 114 - 125
  • [45] Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
    Hadoux, J.
    Elisei, R.
    Brose, M. S.
    Hoff, A. O.
    Robinson, B. G.
    Gao, M.
    Jarzab, B.
    Isaev, P.
    Kopeckova, K.
    Wadsley, J.
    Fuehrer, D.
    Keam, B.
    Bardet, S.
    Sherman, E. J.
    Tahara, M.
    Hu, M. I.
    Singh, R.
    Lin, Y.
    Soldatenkova, V
    Wright, J.
    Lin, B.
    Maeda, P.
    Capdevila, J.
    Wirth, L. J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (20): : 1851 - 1861
  • [46] Mechanisms of disease:: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy
    Drosten, Matthias
    Puetzer, Brigitte M.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (10): : 564 - 574
  • [47] RET signals through focal adhesion kinase in medullary thyroid cancer cells - Discussion
    Singh, B
    Gimm, O
    Chen, H
    Moley, JF
    Kim
    SURGERY, 2004, 136 (06) : 1216 - 1217
  • [48] A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo DISCUSSION
    Weber, Collin J.
    Cohen, Mark S.
    Chen, Herb
    SURGERY, 2010, 148 (06) : 1236 - 1236
  • [49] Routine screening for germline RET mutations is recommended for all patients with medullary thyroid cancer
    Diana L Learoyd
    Bruce G Robinson
    Nature Clinical Practice Endocrinology & Metabolism, 2009, 5 : 6 - 7
  • [50] Ret proto-oncogene mutations in the slovenian population of patients with medullary thyroid cancer
    Sara, Milicevic
    Damijan, Bergant
    Tina, Zagar
    Barbara, Peric
    ONKOLOGIJA, 2020, 24 (01) : 12 - 18